Revolution Medicines, Inc. (RVMD) Stock Research
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Latest price: 201.74 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Mancini Anthony | sell | 2026-09-24 | 117400 |
| Mancini Anthony | sell | 2026-09-25 | 625885.34 |
| ANDERSON ELIZABETH M | sell | 2026-09-22 | 19515 |
| ANDERSON ELIZABETH M | sell | 2026-09-22 | 174585.41 |
| ANDERSON ELIZABETH M | sell | 2026-09-22 | 959805.42 |
| ANDERSON ELIZABETH M | sell | 2026-09-22 | 512227 |
| ANDERSON ELIZABETH M | sell | 2026-09-22 | 291883.05 |
| Mancini Anthony | sell | 2026-09-18 | 347402.16 |
| Kelsey Stephen Michael | sell | 2026-09-16 | 16575.63 |
| Mancini Anthony | sell | 2026-09-16 | 348182.69 |